Modernizing vaccine surveillance systems to improve detection of rare or poorly defined adverse events
from The BMJ
Before vaccines are licensed, their efficacy has to be shown in clinical trials. The trials, however, are generally not powered to evaluate safety. Even phase III trials collect only limited safety data, mostly on common adverse events that occur shortly after vaccination such as local and systemic reactions related to the immunogenicity of the vaccine.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063